Lifetime History of Depression Predicts Increased Amyloid-β Accumulation in Patients with Mild Cognitive Impairment

Alzheimer's Disease Neuroimaging Initiative

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Mounting evidence associates a lifetime history of major depression (LMD) with an increased risk for Alzheimer's disease (AD). Studies have shown that major depression (MD) is strongly linked to pathophysiological markers of AD, such as cortical amyloid-β (Aβ) burden. However, no imaging studies have shown in vivo whether an LMD is linked to increased Aβ accumulation in patients with mild cognitive impairment (MCI) in four cortical regions that have been highly associated with increased Aβ deposition in previous literature: frontal, cingulate, parietal, and temporal. Drawing from the ADNI database, we found that patients with amnestic MCI (aMCI) and an LMD (n = 39) had significantly higher 18F-Florbetapir standardized uptake value ratios, a surrogate measure of Aβ deposition, mainly in the bilateral frontal cortex, compared to patients with aMCI without an LMD (n = 39) (p = 0.02). This difference was not explained by current depressive symptoms, vascular risk factors, or the use of different PET scanners. The results were reliable employing two independent methods for analysis: region-of-interest and voxel-based analyses. Increased Aβ in the bilateral frontal lobes may be a biomarker of depressive symptomology in aMCI patients. Further studies should test whether higher Aβ predicts future conversion into AD in this population.

Original languageEnglish
Pages (from-to)907-919
Number of pages13
JournalJournal of Alzheimer's Disease
Volume45
Issue number3
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Amyloid
Depression
Alzheimer Disease
Frontal Lobe
Cognitive Dysfunction
Biomarkers
Databases
Population

Keywords

  • Alzheimer's disease
  • amyloid-β
  • major depression
  • mild cognitive impairment
  • positron emission tomography

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Lifetime History of Depression Predicts Increased Amyloid-β Accumulation in Patients with Mild Cognitive Impairment. / Alzheimer's Disease Neuroimaging Initiative.

In: Journal of Alzheimer's Disease, Vol. 45, No. 3, 01.01.2015, p. 907-919.

Research output: Contribution to journalArticle

@article{e3a3ff2cb9244f98896d4ae4136522f6,
title = "Lifetime History of Depression Predicts Increased Amyloid-β Accumulation in Patients with Mild Cognitive Impairment",
abstract = "Mounting evidence associates a lifetime history of major depression (LMD) with an increased risk for Alzheimer's disease (AD). Studies have shown that major depression (MD) is strongly linked to pathophysiological markers of AD, such as cortical amyloid-β (Aβ) burden. However, no imaging studies have shown in vivo whether an LMD is linked to increased Aβ accumulation in patients with mild cognitive impairment (MCI) in four cortical regions that have been highly associated with increased Aβ deposition in previous literature: frontal, cingulate, parietal, and temporal. Drawing from the ADNI database, we found that patients with amnestic MCI (aMCI) and an LMD (n = 39) had significantly higher 18F-Florbetapir standardized uptake value ratios, a surrogate measure of Aβ deposition, mainly in the bilateral frontal cortex, compared to patients with aMCI without an LMD (n = 39) (p = 0.02). This difference was not explained by current depressive symptoms, vascular risk factors, or the use of different PET scanners. The results were reliable employing two independent methods for analysis: region-of-interest and voxel-based analyses. Increased Aβ in the bilateral frontal lobes may be a biomarker of depressive symptomology in aMCI patients. Further studies should test whether higher Aβ predicts future conversion into AD in this population.",
keywords = "Alzheimer's disease, amyloid-β, major depression, mild cognitive impairment, positron emission tomography",
author = "{Alzheimer's Disease Neuroimaging Initiative} and Chung, {Jun Ku} and Eric Plitman and Shinichiro Nakajima and Chow, {Tiffany W.} and Chakravarty, {M. Mallar} and Fernando Caravaggio and Philip Gerretsen and Brown, {Eric E.} and Yusuke Iwata and Mulsant, {Benoit H.} and Ariel Graff-Guerrero",
year = "2015",
month = "1",
day = "1",
doi = "10.3233/JAD-142931",
language = "English",
volume = "45",
pages = "907--919",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "3",

}

TY - JOUR

T1 - Lifetime History of Depression Predicts Increased Amyloid-β Accumulation in Patients with Mild Cognitive Impairment

AU - Alzheimer's Disease Neuroimaging Initiative

AU - Chung, Jun Ku

AU - Plitman, Eric

AU - Nakajima, Shinichiro

AU - Chow, Tiffany W.

AU - Chakravarty, M. Mallar

AU - Caravaggio, Fernando

AU - Gerretsen, Philip

AU - Brown, Eric E.

AU - Iwata, Yusuke

AU - Mulsant, Benoit H.

AU - Graff-Guerrero, Ariel

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Mounting evidence associates a lifetime history of major depression (LMD) with an increased risk for Alzheimer's disease (AD). Studies have shown that major depression (MD) is strongly linked to pathophysiological markers of AD, such as cortical amyloid-β (Aβ) burden. However, no imaging studies have shown in vivo whether an LMD is linked to increased Aβ accumulation in patients with mild cognitive impairment (MCI) in four cortical regions that have been highly associated with increased Aβ deposition in previous literature: frontal, cingulate, parietal, and temporal. Drawing from the ADNI database, we found that patients with amnestic MCI (aMCI) and an LMD (n = 39) had significantly higher 18F-Florbetapir standardized uptake value ratios, a surrogate measure of Aβ deposition, mainly in the bilateral frontal cortex, compared to patients with aMCI without an LMD (n = 39) (p = 0.02). This difference was not explained by current depressive symptoms, vascular risk factors, or the use of different PET scanners. The results were reliable employing two independent methods for analysis: region-of-interest and voxel-based analyses. Increased Aβ in the bilateral frontal lobes may be a biomarker of depressive symptomology in aMCI patients. Further studies should test whether higher Aβ predicts future conversion into AD in this population.

AB - Mounting evidence associates a lifetime history of major depression (LMD) with an increased risk for Alzheimer's disease (AD). Studies have shown that major depression (MD) is strongly linked to pathophysiological markers of AD, such as cortical amyloid-β (Aβ) burden. However, no imaging studies have shown in vivo whether an LMD is linked to increased Aβ accumulation in patients with mild cognitive impairment (MCI) in four cortical regions that have been highly associated with increased Aβ deposition in previous literature: frontal, cingulate, parietal, and temporal. Drawing from the ADNI database, we found that patients with amnestic MCI (aMCI) and an LMD (n = 39) had significantly higher 18F-Florbetapir standardized uptake value ratios, a surrogate measure of Aβ deposition, mainly in the bilateral frontal cortex, compared to patients with aMCI without an LMD (n = 39) (p = 0.02). This difference was not explained by current depressive symptoms, vascular risk factors, or the use of different PET scanners. The results were reliable employing two independent methods for analysis: region-of-interest and voxel-based analyses. Increased Aβ in the bilateral frontal lobes may be a biomarker of depressive symptomology in aMCI patients. Further studies should test whether higher Aβ predicts future conversion into AD in this population.

KW - Alzheimer's disease

KW - amyloid-β

KW - major depression

KW - mild cognitive impairment

KW - positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=84925725593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925725593&partnerID=8YFLogxK

U2 - 10.3233/JAD-142931

DO - 10.3233/JAD-142931

M3 - Article

VL - 45

SP - 907

EP - 919

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 3

ER -